CBD may control seizures by regulating methionine through a previously unknown metabolic pathway

Using the model organism Dictyostelium, researchers identified that CBD activity depends partly on the glycine cleavage system, linked to folate one-carbon metabolism (FOCM). CBD directly inhibited methionine synthesis. In a Dravet syndrome mouse model, one-carbon metabolism components including methionine were drastically altered. In an in vitro rat seizure model, methionine levels were elevated during seizures and reduced by CBD treatment.

Multi-model approach: unbiased screen in Dictyostelium to identify CBD-interacting proteins; validation in Dravet syndrome mouse model (brain tissue analysis); functional testing in acute in vitro rat hippocampal seizure model. Methionine and one-carbon metabolites measured across all models.

Despite FDA approval of Epidiolex for Dravet syndrome, CBD mechanism of action was poorly understood. This study identifies an entirely new metabolic pathway (one-carbon metabolism/methionine) that may explain how CBD controls seizures.

One-carbon metabolism is fundamental to cellular function. If CBD anti-seizure effects work through this pathway, it opens entirely new drug targets for epilepsy treatment and may explain why CBD helps some seizure types but not others.

Initial discovery in a simple model organism (Dictyostelium); animal models only; mechanism not yet confirmed in human epilepsy tissue; does not establish dose-response in mammals; the multiple-model approach increases confidence but each individual model has limitations.